Suzhou Lung Care Medical Technologies Co., Ltd.

Suzhou Lung Care Medical Technologies Co. , Ltd. develops advanced diagnostic and therapeutic solutions for lung cancer management, focusing on innovation to enhance patient outcomes through precise medical technologies. Founded in 2012 in Suzhou, China, Suzhou Lung Care Medical Technologies Co.

, Ltd. specializes in medical solutions for lung cancer. The company has successfully completed 4 funding deals, with the most recent being in June 2020 when it raised venture funding from Shenyang Dehong Chuangzhan Equity Investment and CITIC Goldstone Fund Management. Lungcare Medical specializes in advanced diagnostic and therapeutic solutions for early-stage lung cancer management.

Core offerings include electromagnetic navigation technology, virtual bronchoscopy systems, and three-dimensional CT imaging equipment, enhancing the precision of lung cancer diagnoses and facilitating minimally invasive treatment procedures. Their technology addresses critical healthcare needs by improving patient outcomes through real-time navigation and localization of pulmonary lesions, serving hospitals, clinics, and healthcare facilities across China, as well as select markets in Europe and Asia. Lungcare Medical operates on a direct-to-business model, providing products and services primarily to hospitals and healthcare institutions. The revenue structure is based on direct sales of diagnostic equipment and therapeutic devices essential for lung cancer treatment.

Partnerships with healthcare facilities support comprehensive solutions including installation, training, and ongoing support. Their pricing strategy accommodates the specific needs of medical institutions, ensuring access to advanced technology for improved patient care, characterized by one-time purchases and potential service agreements for maintenance and support. Looking ahead, Suzhou Lung Care Medical Technologies Co. , Ltd.

aims to expand its product line, focusing on upcoming innovations in lung cancer diagnostics and treatment technologies. The company is actively seeking to enter new markets in Europe and Asia by 2025. The funds raised in June 2020 will support these initiatives, aiding in product development and market entry strategies.